Landmark Asthma Study Demonstrates Device Choice Determines Asthma Control
Plattsburgh, NY, USA -- Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration. Research has shown that even when using the same metered-dose inhaler (MDI), not all valved holding chambers perform equally well.
A landmark real-world study involving more than 18,000 asthma patients has demonstrated superior asthma control with the AEROCHAMBER PLUS® FLOW-VU® antistatic Valved Holding Chamber (VHC) compared with other chamber devices. According to the study, published in Pulmonary Therapy, use of the AEROCHAMBER PLUS® FLOW-VU® antistatic chamber resulted in delayed time to first exacerbation, fewer asthma-related emergency department visits, and lower exacerbation-related costs than control chambers.
Asthma is a common respiratory condition that affects an estimated 24.6 million people in the United States. Almost half of them, including nearly 3 million children, experience one or more asthma attack in a year.
As opposed to systemic medications, inhalation is the recommended way to administer asthma medications because it directly targets the drug to the lungs while reducing potential side effects. Inhaled corticosteroids and bronchodilators administered by MDIs are the mainstay of long-term asthma treatment, the goals of which are to improve symptoms and prevent the occurrence of exacerbations.
Poor inhaler operation by users is common, resulting in less of the delivered drug reaching the lungs. Instead, much of it is deposited on the back of the throat (oropharyngeal deposition) and then swallowed. Research shows that between 28% and 68% of patients do not use inhalers well enough to benefit from prescribed medication. In addition, 25% of costs associated with inhalers is wasted due to poor inhaler technique.
Chambers are designed to reduce oropharyngeal deposition by changing the particle size distribution of the inhaled aerosol, and by holding the aerosol in the chamber until the patient is ready to inhale, which reduces the need for good coordination between inhalation and inhaler actuation. Effectiveness of these devices can be adversely affected by the design, including the chamber electrostatic charge, a commonly reported cause of inconsistent medication delivery.
Global respiratory guidelines recommend the use of chambers to improve MDI drug delivery. American Thoracic Society and American Association for Respiratory Care Clinical Practice Guidelines state that the addition of a chamber is recommended and helpful.[9,10] Research also indicates that patients who use a chamber with an MDI have better asthma control than those using an MDI alone.
In this new study, Dr. Chakkarin Burudpakdee (QuintilesIMS, Fairfax, VA, USA) and colleagues compared the effects of the antistatic AEROCHAMBER PLUS® FLOW-VU® aVHC and control chambers on treatment outcomes, resource use, and healthcare costs in a real-world asthma population. More than 18,000 patients were included from an adjudicated claims database containing medical and pharmacy claims for more than 150 million U.S. health plan members.
The analysis showed that among patients with at least 30 days of follow-up, those using the AEROCHAMBER PLUS® FLOW-VU® antistatic VHC experienced a delay in the time to first exacerbation and had fewer asthma-related emergency room visits. In addition, exacerbation-related costs were lower when compared to those using the control (non-antistatic) chambers. A trend toward lower exacerbation rates per patient for the AEROCHAMBER PLUS® FLOW-VU® aVHC was sustained throughout the 12 months of the study.
"This landmark study using a large volume of real-world evidence generated from thousands of patients shows the value of optimizing drug delivery in asthma management and further supports that chambers are not interchangeable," said co-author Dominic Coppolo, MBA, RRT, FAARC, Vice President Clinical Strategy and Development. "The reduction in exacerbation incidents among users of the AEROCHAMBER PLUS® FLOW-VU® chamber is particularly notable because experiencing an exacerbation is a risk factor for future exacerbation events-and minimizing exacerbation risk is a key goal of treatment."
"The European Medicines Agency recommended in 2009 that development of a MDI should include the testing of at least one specific, named chamber, and that any substitution must be supported by appropriate in vitro or clinical data demonstrating equivalence," he said. "We presented laboratory data at the recent Respiratory Drug Delivery Europe meeting that confirmed that not all chambers perform equally well with the same MDI, which underlines the importance of recognizing the impact and potential risks of substituting one device for another."
Words or phrases accompanied by ® are trademarks and registered trademarks of Monaghan Medical Corporation or an affiliate of Monaghan Medical Corporation. © 2017 Monaghan Medical Corporation.
1 Nagel MW, Suggett JA. Equivalence evaluation of valved holding chambers (VHCs) with albuterol pressurized metered dose inhaler (pMDI). Respiratory Drug Delivery Europe; April 25-28, 2017, 2017; Nice, France.
2 Burudpakdee C, Kushnarev V, Coppolo D, Suggett J. A retrospective study of the effectiveness of the AeroChamber Plus® Flow-Vu® Antistatic Valved Holding Chamber for asthma control. Pulmonary Therapy. 2017. http://doi.org/10.1007/s41030-017-0047-1. Accessed July 14.
3 Asthma Facts. United States Environmental Protection Agency. EPA-402-F-04-019. May 2017.
4 Global Initiative for Asthma: Global strategy for asthma management and prevention, 2017. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention Accessed November 2017.
5 Price D, Bosnic-Anticevich S, Briggs A, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respiratory Medicine. 2013;107(1):37-46.
6 Fink JB, Rubin BK. Problems with Inhaler Use: A Call for Improved Clinician and Patient Education. Respir Care 2005;50(10):1360-74.
7 Lavorini F, Fontana GA. Targeting drugs to the airways: The role of spacer devices. Expert opinion on drug delivery. 2009;6(1):91-102.
8 Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respiratory care. 2007;52(3):283-300.
9 Chung KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal 2014 ;43:343-373.
10 Ari A, et al. Aerosol Delivery Device Selection for Spontaneously Breathing Patients:2012. Respir Care 2012;57(4):613- 626.
11 Levy ML, et al. Asthma patients' inability to use a pressurized metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the Global Initiative for Asthma (GINA) strategy: a retrospective analysis. Prim Care Respir J. 2013; Dec;22(4):406-11.
12 Ammari WG, et al. Evaluation of asthma control, parents' quality of life and preference between AeroChamber Plus and AeroChamber Plus Flow-Vu spacers in young children with asthma. J Asthma 2015; 52(3):301-7.
About Monaghan Medical Corporation
Monaghan Medical Corporation (MMC) offers leading aerosol drug delivery devices and respiratory management products including AeroEclipse® II BAN, AeroChamber Plus® aVHC and the Aerobika® device exclusively in the United States. MMC's strength lies in product development around core capabilities in mechanical design complimented by collaboration with a state-of-the-art aerosol research laboratory. MMC focuses on developing cost-efficient, outcome-based solutions for its customers. (http://www.monaghanmed.com)
About AEROCHAMBER® brand valved holding chambers, including the AEROCHAMBER PLUS® FLOW-VU® anti-static chamber
Developed in 1983 to address the needs of asthma and COPD patients having difficulty in taking their MDI medications correctly, the AEROCHAMBER® brand of chamber has innovated continuously to improve patient ease of use and quality of life as well as clinical outcomes and healthcare system savings.
• The AEROCHAMBER PLUS® valved holding chamber is the leading global chamber brand, with safety and efficacy validated in numerous third-party clinical evaluations among various patient populations. It is the chamber most recommended by leading MDI pharmaceutical companies.
• AEROCHAMBER PLUS® FLOW-VU® chamber is an antistatic chamber designed to deliver the intended prescribed dose via the MDI, similar to using an MDI with perfect technique. An additional feature is the incorporation of the FLOW-VU® inhalation indicator for the caregiver to observe effective inhalation. A recent study showed that caregiver quality of life improved almost four-fold when using the AEROCHAMBER PLUS® chamber with FLOW-VU® indicator versus the same chamber without the indicator. The FLOW-VU® indicator provides real-time feedback confirming an effective inhalation and that there are no leakages of ambient air into the space between facemask and face, which could prevent medication delivery altogether. (http://www.monaghanmed.com/AeroChamber-Plus-Flow-Vu-aVHC2)
About the study
Data for more than 18,000 patients with an asthma diagnosis were analysed from the QuintilesIMS Real-World Data Adjudicated Claims Database (PharMetrics Plus) between 1/2010 and 8/2015-9,325 using the AEROCHAMBER PLUS® FLOW-VU® antistatic VHC and a propensity-matched comparison cohort of 9,325 non-antistatic VHCs. Exacerbation incident rates (IR), time to first exacerbation using Kaplan-Meier survival analysis, occurrence of exacerbations, and healthcare resource use and costs were compared.
• Exacerbation IR/100 person-days (95% CI) was significantly higher in the control device cohort than the antistatic chamber cohort (0.161 [0.150-0.172] vs.0.137 [0.128-0.147]); more patients in the antistatic chamber cohort remained exacerbation free.
• 4,293 patients in each cohort were followed up for (greater than or equal to)12 months, during which there was a trend for patients in the antistatic VHC group to be less likely (10-12%) to experience an exacerbation. Fewer patients using the antistatic VHC had an ED visit compared with those in the control group (10.8% vs. 12.4%).
• Exacerbation-related costs for the antistatic VHC cohort were 23%, 25%, 20%, and 12% lower than the control device cohort at 1, 6, 9, and 12 months, respectively.
For clinical inquiries, please contact:
Dominic P. Coppolo, MBA, RRT, FAARC
Vice President Clinical Strategy and Development
Monaghan Medical Corporation
5 Latour Ave # 1600, Plattsburgh, NY 12901
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Landmark Asthma Study Demonstrates Device Choice Determines Asthma Control here
News-ID: 842295 • Views: 287
More Releases from Monaghan Medical Corporation
Significant Reductions in Costly Pulmonary Complications with Use of Drug-Free D …
Plattsburgh, NY, USA -- Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the AEROBIKA® oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.(1) The retrospective database analysis including 288 patients undergoing cardiac, thoracic or upper abdominal surgery suggests that use of the AEROBIKA® OPEP device in addition to standard
New Published Evidence Reinforces the Importance of Device Choice in Asthma Cont …
Two new publications build on previous evidence that not all devices are equally effective in delivering asthma control. Plattsburgh, NY, USA -- A recent article in Pulmonary Pharmacology and Physiology provides in vitro evidence that the AEROCHAMBER PLUS® FLOW-VU® valved holding chamber (or spacer) delivers aerosolized drug more effectively than other chambers, a view further supported in a new literature review published in Therapeutic Advances in Respiratory Disease. The use of spacers
Significant Cost Reduction in COPD Care With Simple, Drug-free Device
Aerobika® OPEP device proves to be a cost-effective treatment option in the management of post-exacerbation COPD patients. Plattsburgh, NY, USA -- The Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device (Monaghan Medical Corporation) is a cost-effective treatment option in the management of COPD exacerbations, according to a study published October 20th in the International Journal of COPD. This study, which used data from the published literature and national fee schedules to model
Monaghan Medical Corporation Receives Innovative Technology Designation from Viz …
Designation recognizes products that bring improvements to the health care industry. Plattsburgh, NY, USA -- Monaghan Medical Corporation announced its AEROBIKA® Oscillating Positive Expiratory Pressure (OPEP) device (http://www.aerobika.us) has received a 2017 Innovative Technology designation from Vizient, Inc. (http://www.vizientinc.com), the largest member-driven health care performance improvement company in the country. The designation was based on direct feedback from hospital experts who interacted with the AEROBIKA® OPEP device at the Vizient Innovative
More Releases for MDI
Global Diphenylmethane Diisocyanate Mdi Industry Research Report Growth Trends A …
This study focuses on the production side and consumption side of Diphenylmethane Diisocyanate (MDI), presents the global Diphenylmethane Diisocyanate (MDI) market size by manufacturers, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025. In terms of production side, this report researches the Diphenylmethane Diisocyanate (MDI) capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and product type. In terms of
Current Trends and Future Growth of Methylene Diphenyl Di-isocyanate (MDI) Marke …
Qyresearchreports include new market research report Global Methylene Diphenyl Di-isocyanate (MDI) Market Professional Survey Report 2018 to its huge collection of research reports. This report studies the Methylene Diphenyl Di-isocyanate (MDI) market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Methylene Diphenyl Di-isocyanate (MDI) market by product
Global Polymeric MDI Market 2018 - Bayer, WanHua, Basf, Huntsman
The statistical surveying information incorporated into the Polymeric MDI report is the aftereffect of significant essential and optional research exercises. The report fragments the worldwide market for Polymeric MDI based on makers, item compose, applications, and Region. In this report, each fragment is contemplated completely and measurements are introduced in detail. The report offers an exact outline of the worldwide Polymeric MDI advertise covering key factors, for example, drivers and
Methylene Diphenyl Diisocyanate (MDI) Market will Register a CAGR of 5.5% throu …
A recent market study by Transparency Market Research (TMR) states that the global methylene diphenyl diisocyanate (MDI) market is expected to grow at a CAGR of 6.1% between 2011 and 2016. Transparency Market Research, a market intelligence company based in the U.S., forecasts that the global MDI market will be valued at US$16 billion in 2016. Additionally, in terms of volume, the global MDI market is forecast to total 6.0 million tons
Methylene Diphenyl Di-isocyanate (MDI) Market - Wanhua, BASF, Huntsman, Covestro
Apex Research, recently published a detailed market research study focused on the "Methylene Diphenyl Di-isocyanate (MDI) Market" across the global, regional and country level. The report provides 360° analysis of "Methylene Diphenyl Di-isocyanate (MDI) Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Methylene Diphenyl Di-isocyanate (MDI) industry, and
Global Methylene Diphenyl Isocyanate (MDI) Market 2017 - WanHua, Tosoh
The motive of this strategic research report entitled "Global Methylene Diphenyl Isocyanate (MDI) Market 2017" is to provide company officials, industry investors, and industry members with consequential insights to enable them make reliable strategic decisions regarding the opportunities in the global Methylene Diphenyl Isocyanate (MDI) market. Key Notes On Methylene Diphenyl Isocyanate (MDI) Market: "Global Methylene Diphenyl Isocyanate (MDI) Market 2017 "offers crucial insights into the global Methylene Diphenyl Isocyanate (MDI) market